INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Sustained Prominence: Indero Presents High‑Impact Clinical Research at AAD Late‑Breaking Sessions

Author picture

Indero’s Founder and Executive Chairman, Dr. Robert Bissonnette, took the stage at the American Academy of Dermatology (AAD) Annual Meeting on March 28, 2026, in Denver, Colorado. During the Late-Breaking Session 1, Dr. Bissonnette presented results from a phase II Pfizer-sponsored study, managed by Indero, entitled Efficacy and Safety of Abrocitinib in Patients with Chronic Hand Eczema: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial.

This study enrolled over 80 patients in North America and Europe, with Innovaderm, Indero’s clinical research unit, serving as the highest‑performing investigational site in North America.

Indero is proud to contribute to advancing therapeutic options and improving the quality of life for individuals living with chronic dermatologic conditions.

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction
Linkedin

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.